Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
PT Jayamas Medica Industri Tbk's 3-Year RORE % for the quarter that ended in Mar. 2026 was 17.33%.
ISX:OMED's 3-Year RORE % is ranked better than 71.89% of 772
companies
in the Medical Devices & Instruments industry
Industry Median: -4.05
vs ISX:OMED: 17.33
PT Jayamas Medica Industri Tbk (ISX:OMED) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
PT Jayamas Medica Industri Tbk 3-Year RORE % Related Terms
PT Jayamas Medica Industri Tbk 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk 3-Year RORE % Chart
ISX:OMED vs ISRG, BDX, MDLN: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Jayamas Medica Industri Tbk 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where PT Jayamas Medica Industri Tbk's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
PT Jayamas Medica Industri Tbk (ISX:OMED) has a 3-Year RORE % of 17.33 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PT Jayamas Medica Industri Tbk and its competitors. According to the industry distribution chart, PT Jayamas Medica Industri Tbk ranks #217 out of 772 companies in the Medical Devices & Instruments industry, placing it in the top 28.1%.
Is PT Jayamas Medica Industri Tbk's 3-Year RORE % too high?
PT Jayamas Medica Industri Tbk's current 3-Year RORE % is 17.33. Based on the distribution chart, PT Jayamas Medica Industri Tbk ranks #217 out of 772 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Jayamas Medica Industri Tbk ranks #217 out of 772 companies for 3-Year RORE %. This puts PT Jayamas Medica Industri Tbk in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PT Jayamas Medica Industri Tbk and its competitors. PT Jayamas Medica Industri Tbk's current 3-Year RORE % is 17.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp239.12, compared to a current price of Rp218.00 — trading 8.8% below its estimated fair value. The current 3-Year RORE % is 17.33. PT Jayamas Medica Industri Tbk's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current 3-Year RORE % is 17.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp218.00 is trading 8.8% below its estimated GF Value™ of Rp239.12.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
3-Year RORE %: 17.33
GF Value™: Rp239.12 vs. price of Rp218.00 (8.8% below fair value)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
91GF Score
Get the complete analysis for ISX:OMED
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
